(Desert Hot Springs, California, USA) – Royal Emerald Pharmaceuticals (REP) is poised to receive the first-of-its-kind federal (DEA) license to research, develop and manufacture medicines derived from THC and CBD. Royal Emerald’s mission is to be leaders in the pharmaceutical field by creating non-addictive medicines for veterans, law enforcement and first responders suffering from ailments, such as, PTSD, pain, anxiety, depression, sleep apnea, opiate addiction and other ailments.
“Our veterans and first responders have paid a tremendous price sacrificing for the betterment of our communities. I am dedicated to repaying their efforts with the best-in-class medicines to benefit society’s heroes,” said Royal Emerald’s CEO Mark Crozier.
“’Safe, effective, and non-addictive medicines,’ is the motto that drives our research. We are currently researching new and safer Active Pharmaceutical Ingredients (APIs) and Botanical Raw Materials (BRMs) that will form the basis of our medicines. Our company seeks only the most current, innovative, and industry-accepted research to ensure our position as a leader in this fast-paced and ever-changing market,” Crozier said.
REP will provide state-of-the-art medicines and active pharmaceutical ingredients derived from THC and CBD to the Drug Enforcement Agency (DEA) registrants and government agencies. The company is a private corporation with a federal government license pending approval. Once granted, REP will be the “first in the nation” to receive this federal approval.
“We adhere to the highest standards and quality measures in our labs to ensure that our products exceed consumer expectations. We guarantee superior quality medicines by complying with current Good Manufacturing Practices (cGMP) established by the Food and Drug Administration (FDA). Our scientists and team of experts are experienced in drug research and development, ensuring our products are consistent, pure and safe for consumers,” he added.
Crozier, along with most of the management team, are veterans and retired first responders who understand the everyday struggles these targeted groups face in their line of work. Crozier started REP in 2017 to combat the medical issues our veterans and first responders face during and after their service.